Myriad Genetics Reports Fiscal Second-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Myriad Genetics (MYGN) PT Raised to $37 at Needham & Company
February 6, 2019 8:05 AM ESTNeedham & Company analyst Stephen Unger raised the price target on Myriad Genetics (NASDAQ: MYGN) to $37.00 (from $36.00) while maintaining a Strong Buy rating.
Unger commented, "We are updating our financial model for MYGN following last night's release of FY2Q19 results. Our... More
Myriad Genetics (MYGN) Misses Q2 EPS by 3c; Offers 3Q & FY19 EPS/Revenue Outlook
February 5, 2019 4:31 PM ESTMyriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.38, $0.03 worse than the analyst estimate of $0.41. Revenue for the quarter came in at $216.8 million versus the consensus estimate of $216.73 million.
"This quarter we saw a return to revenue growth for our hereditary cancer business, an... More
